Related Experiment Video
Updated: Jun 22, 2026
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
[Not Available]
Antonio C Campos de Carvalho1, Regina C S Goldenberg, Linda A Jelicks
1Instituto Nacional de Cardiologia, 22240-006 Rio de Janeiro, RJ, Brazil.
Insights
Bone marrow cell transplantation shows promise for treating advanced Chagas disease heart conditions. This innovative therapy may reduce heart damage and improve outcomes for patients with chagasic cardiomyopathy.
Area of Science:
- Cardiology
- Infectious Diseases
- Regenerative Medicine
Background:
- Chagas disease, caused by Trypanosoma cruzi, is a leading cause of cardiomyopathy in Latin America.
- Advanced chagasic cardiomyopathy often leads to heart failure refractory to medical treatment.
- Current treatments like heart transplantation have significant risks and complications.
Purpose of the Study:
- To evaluate the safety and efficacy of autologous bone marrow transplantation in patients with end-stage chagasic heart disease.
- To build upon promising results from animal studies demonstrating bone marrow's potential to reduce cardiac inflammation and fibrosis.
Main Methods:
- Assessment of autologous bone marrow transplantation safety in human patients.
- Utilizing cardiac magnetic resonance imaging to evaluate treatment effects on cardiac structure and function in preclinical models.
Main Results:
- Preclinical studies in mice indicated that bone marrow transplantation reduced cardiac inflammation and fibrosis.
- Cardiac MRI in animal models showed amelioration of right ventricular enlargement caused by the infection.
- Initial safety assessments in human patients with end-stage chagasic heart disease are encouraging.
Conclusions:
- Autologous bone marrow transplantation is a potentially safe and effective therapeutic strategy for chagasic end-stage heart disease.
- Further clinical studies are warranted to confirm the long-term benefits and optimize treatment protocols.
Abstract:
Chagas disease which is caused by the parasite Trypanosoma cruzi is an important cause of cardiomyopathy in Latin America. In later stages chagasic cardiomyopathy is associated with congestive heart failure which is often refractory to medical therapy. In these individuals heart transplantation has been attempted. However, this procedure is fraught with many problems attributable to the surgery and the postsurgical administration of immunosuppressive drugs. Studies in mice suggest that the transplantation of bone-marrow-derived cells ameliorates the inflammation and fibrosis in the heart associated with this infection. Cardiac magnetic resonance imaging reveals that bone marrow transplantation ameliorates the infection induced right ventricular enlargement. On the basis of these animal studies the safety of autologous bone marrow transplantation has been assessed in patients with chagasic end-stage heart disease. The initial results are encouraging and more studies need to be performed.
